Double-Blind Randomized Phase II Trial of Carboplatin and Pemetrexed With or Without OGX-427 in Patients With Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (The Spruce Clinical Trial)

Trial Profile

Double-Blind Randomized Phase II Trial of Carboplatin and Pemetrexed With or Without OGX-427 in Patients With Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (The Spruce Clinical Trial)

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Apatorsen (Primary) ; Carboplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms Spruce
  • Most Recent Events

    • 12 May 2017 Status changed from active, no longer recruiting to completed.
    • 05 May 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
    • 03 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top